AbbVie (ABBV) announced submission of a Biologics License Application to the U.S.FDA for trenibotulinumtoxinE for the treatment of moderate to severe glabellar lines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: